title: Sodium fluoride therapy.
abstract: As a medical treatment for otospongiosis-otosclerosis, sodium fluoride influences the underlying bony changes in the labyrinth so as to arrest or prevent the onset of hearing loss. Sodium fluoride is an enzyme inhibitor and reduces osteoclastic bone resorption and, if the dosage is more than 60 mg a day, may rebuild pseudohaversian bone.
authors.affiliation: Clinique d'Otologie Jean Causse Traverse de Béziers, Colombiers, France.
authors.forename: J R
authors.initials: JR
authors.lastname: Causse
authors.forename: J B
authors.initials: JB
authors.lastname: Causse
authors.forename: J
authors.initials: J
authors.lastname: Uriel
authors.forename: J
authors.initials: J
authors.lastname: Berges
authors.forename: G E
authors.initials: GE
authors.lastname: Shambaugh
authors.forename: P
authors.initials: P
authors.lastname: Bretlau
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001862:Bone Resorption / Q000188:drug therapy / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D007758:Ear, Inner / Q000187:drug effects*; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010040:Otosclerosis / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D011446:Prospective Studies; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D010919:Placebos; D012969:Sodium Fluoride